TILVANCE
LIVE

Serial Number

97320354

Owner

Iovance Biotherapeutics, Inc.

Attorney

Carla B. Oakley

First Use Date

Jul 10, 2026

Filing Date

Mar 18, 2022

Add to watchlist:

No watchlists yet
View on USPTO

TILVANCE Trademark

Serial Number: 97320354

TILVANCE is a trademark filed by Iovance Biotherapeutics, Inc. on March 18, 2022. The trademark is classified under Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Iovance Biotherapeutics, Inc.

San Carlos, CA 94070

Entity Type: 03

Trademark Details

Filing Date

March 18, 2022

Registration Date

Not Registered

First Use Anywhere

July 10, 2026

First Use in Commerce

July 10, 2026

Published for Opposition

May 16, 2023

Goods & Services

Medical services, namely, resection of tumor and modifying cells for the treatment of cancer and other diseases and medical conditions; immunotherapy treatments; medical diagnostic and treatment services; providing information in the field of oncology and immunotherapy treatments; providing medical information, consultancy and advisory services; providing a web site featuring medical information and information relating to pharmaceuticals; providing medical and health information relating to pharmaceuticals; medical, telehealth, remote care and virtual health care services, namely, providing medical services and consultation over the telephone and via the Internet through the use of personal computers, smartphones, tablets, and mobile wireless devices via video, email, or a global computer network; providing medical services, telehealth services in the nature of telemedicine services, remote health care services, and virtual health care services via a web site and mobile app featuring health and medical information; providing telemedicine and virtual health care services for the diagnosis, consultation, and treatment of oncological or immune system conditions; medical counseling; consulting services in the field of medical care; medical, immunotherapy and pharmaceutical consultation; medical analysis services for diagnostic and treatment purposes provided by medical laboratories

providing medical and scientific research information to others in the field of pharmaceuticals and clinical trials

Filing History

STATEMENT OF USE PROCESSING COMPLETE
Jul 23, 2026 SUPC
USE AMENDMENT FILED
Jul 10, 2026 IUAF
TEAS STATEMENT OF USE RECEIVED
Jul 10, 2026 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 5, 2026 EXRA
SOU EXTENSION 5 GRANTED
Jun 5, 2026 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jun 4, 2026 AITU
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 7, 2026 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 7, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 7, 2026 REAP
SOU TEAS EXTENSION RECEIVED
Jan 9, 2026 EEXT
SOU EXTENSION 5 FILED
Jan 8, 2026 EXT5
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 13, 2025 EXRA
SOU EXTENSION 4 GRANTED
Jun 13, 2025 EX4G
SOU EXTENSION 4 FILED
Jun 12, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
Jun 12, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 4, 2025 EXRA
SOU EXTENSION 3 GRANTED
Jan 4, 2025 EX3G
SOU EXTENSION 3 FILED
Jan 4, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Jan 3, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 9, 2024 EXRA
SOU EXTENSION 2 GRANTED
Jul 9, 2024 EX2G
SOU EXTENSION 2 FILED
Jul 9, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Jul 9, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 16, 2023 EXRA
SOU EXTENSION 1 GRANTED
Dec 14, 2023 EX1G
SOU EXTENSION 1 FILED
Dec 14, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Dec 14, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 11, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 16, 2023 NPUB
PUBLISHED FOR OPPOSITION
May 16, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 26, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 13, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 12, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 11, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 11, 2023 TROA
NOTIFICATION OF PRIORITY ACTION E-MAILED
Oct 19, 2022 GPRN
PRIORITY ACTION E-MAILED
Oct 19, 2022 GPRA
PRIORITY ACTION WRITTEN
Oct 19, 2022 CPRA
ASSIGNED TO EXAMINER
Oct 7, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 23, 2022 NWOS
NEW APPLICATION ENTERED
Mar 22, 2022 NWAP